Work

Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is effective and safe in the treatment of hyperlipidemia in chronic kidney disease stage 3 – 4

Year: 2026

Type: article

Source: International Journal of Clinical Pharmacology and Therapeutics

DOI: 10.5414/cp204964

Authors: Hongxu Zhu, Yufeng Chang, Qi Jin

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7160871889

FWCI:

Cites:

Cited by:

Related to: